Xilio Therapeutics, Inc. (NasdaqCM: XLO)
Health Care · Biotechnology · US
$9.19
-0.43% today · -5.8% 1Y
Xilio Therapeutics, Inc. (NasdaqCM: XLO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $60.73M and employs 76 people.
Over the last twelve months the share price has lost 5.8%, trading between 6.47 and 12.74.
Tweenvest scores Xilio Therapeutics, Inc. across four factors: quality 28/100, value 49/100. Its strongest factor is value.
XLO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $60.73M
- Revenue (TTM)
- $64.09M
- P/E
- —
- EPS
- -3.32
- Dividend yield
- —
- Beta (5Y)
- -0.12
- 52-week high
- $12.74
- 52-week low
- $6.47
- Avg volume (3M)
- —
- Shares outstanding
- 6.58M
- Employees
- 76
- Next earnings
- —
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
- ISIN
- US98422T2096
- Founded
- 2016
- Listed since
- Oct 22, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.